Similar articles

• Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

  Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Lanford RE, et al. Science. 2010 Jan 8;327(5962):198-201. doi: 10.1126/science.1178178. Epub 2009 Dec 3. Science. 2010. PMID: 19965718 Free PMC article.
• MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.

  Nunnari G, Schnell MJ. Nunnari G, et al. Front Biosci (Schol Ed). 2011 Jun 1;3(3):1032-7. doi: 10.2741/207. Front Biosci (Schol Ed). 2011. PMID: 21622252
• Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro.

  Alotte C, Martin A, Caldarelli SA, Di Giorgio A, Condom R, Zoulim F, Durantel D, Hantz O. Alotte C, et al. Antiviral Res. 2008 Dec;80(3):280-7. doi: 10.1016/j.antiviral.2008.06.011. Epub 2008 Jul 14. Antiviral Res. 2008. PMID: 18625270
• MicroRNA-targeting therapeutics for hepatitis C.

  Baek J, Kang S, Min H. Baek J, et al. Arch Pharm Res. 2014 Mar;37(3):299-305. doi: 10.1007/s12272-013-0318-9. Epub 2014 Jan 3. Arch Pharm Res. 2014. PMID: 24385319 Review.
• Oligonucleotide-based therapeutic options against hepatitis C virus infection.

  Trepanier JB, Tanner JE, Alfieri C. Trepanier JB, et al. Antivir Ther. 2006;11(3):273-87. Antivir Ther. 2006. PMID: 16759043 Review.